RTP Mobile Logo

Subscription | Cancel Subscription Request

Please fill out the form below if you no longer wish to receive our email programs. Allow a week before subscription canceled.

To subscribe to our programs, click here.

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

GUPerspectives16/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, urologists and radiation oncologists.

SanAntonioBC15/Video

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of breast cancer (BC).

OVERVIEW OF ACTIVITY
BC remains the most frequently diagnosed cancer in women, and in 2015 it is estimated that the disease culminated in 234,190 new cases and 40,730 deaths in the United States alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with BC has increased substantially, as has the population “at risk” for recurrent disease.

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

CME Information and Faculty Disclosures

OVERVIEW OF ACTIVITY

5MJCASH2016

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

NeoadjuvantBC16/Patients

TARGET AUDIENCE
This activity is intended for medical oncologists and surgeons involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

NeoadjuvantBC16

TARGET AUDIENCE
This activity is intended for medical oncologists and surgeons involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

QualityCareTT115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists.

MCRC115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of colorectal cancer (CRC).

MCRC115

OVERVIEW OF ACTIVITY

LCU215

OVERVIEW OF ACTIVITY

GrandRoundsProstate15

TARGET AUDIENCE
This activity is intended for urologists, medical and radiation oncologists and other healthcare providers involved in the treatment of prostate cancer.

OVERVIEW OF ACTIVITY
Prostate cancer is the most frequently diagnosed cancer in men, with more than 50% of all cases found in individuals aged 65 years or older. Among the 220,800 new diagnoses of prostate cancer estimated within the United States in 2015, more than 90% will be discovered in the local and regional stages of disease where 5-year survival estimates approach 100% with current therapeutic intervention. This statistic emphasizes the importance of early detection, the effectiveness of current treatments and the natural history of the disease.